about
sameAs
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersSDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paragangliomaThe Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational familyGenome-wide association study identifies novel breast cancer susceptibility lociA high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families13th General Meeting of The Breast Cancer Linkage Consortium, November 29-December 1, 1999, Amsterdam, The NetherlandsThe SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency.Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskGenomic structure of the human PLZF geneA high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor regionLow-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsLarge-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repairCombined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancersMutation of SDHB is a cause of hypoxia-related high-altitude paragangliomaClinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patientsComplete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancerPrevalence of BRCA1 in a hospital-based population of Dutch breast cancer patientsGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSErratum to: Making sense of big data in health research: towards an EU action planMaking sense of big data in health research: Towards an EU action planRare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancersRare mutations in XRCC2 increase the risk of breast cancerLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.Mutations in SDHD, a mitochondrial complex II gene, in hereditary paragangliomaGenetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage ConsortiumGenetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European DescentNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.Leiden Open Variation Database of the MUTYH gene.Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer.Survival in hereditary breast cancer associated with germline mutations of BRCA2.Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.Alpha satellite DNAs on chromosomes 10 and 12 are both members of the dimeric suprachromosomal subfamily, but display little identity at the nucleotide sequence level.A procedure for the detection of linkage with high density SNP arrays in a large pedigree with colorectal cancer.Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies.Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.A family history of breast cancer will not predict female early onset breast cancer in a population-based settingThe first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients
P50
Q21144874-90E31663-67B4-423B-84A6-F5A7FC612A32Q24317137-7145E263-19AD-4CC2-859C-6D80EB9E0604Q24599202-2C5B826C-3A29-403C-A4E1-488437CA6934Q24645441-AFBC65F4-84E3-4702-B29C-19C6D9723DA6Q24680760-6504BD02-AC85-4958-9C58-C0635BF945B4Q24803103-18A07A1C-059E-457A-8C84-6CD9CA36B0A9Q25255676-7344FF9C-45CA-45CC-9CEC-ADF479A73558Q25255910-5A9053E5-9D22-4E1D-BD00-8AF3C330846FQ27008356-ADB1F0AA-974F-48C9-B49E-5972EC9E79EAQ28141254-B0EEF97C-A768-4778-B8F6-33B12E4AADAEQ28213685-72A9B5F2-5D1C-4814-BC93-6F41F35C9BAFQ28215462-5ADC50F9-5921-4335-9FD1-0006E6A2E4DAQ28267893-C90CB9E0-E3A8-4B7A-9845-1E49E828C774Q28270798-9E0BFDCF-07B6-4D56-9004-53E0EDB44610Q28286565-E4888593-B8C7-47FC-B625-2B17BBE8B737Q28365020-EB882A7D-D13A-4CC6-9733-3C0BB1957DA3Q28377995-74A8A502-1180-4734-8A77-B1F18AD38AE2Q28384196-21B4FD3C-7412-4CED-83D1-3296A7B50370Q28388497-28D98D43-8242-47EE-9F2C-1FC8C471362CQ28584533-CC7A0566-08F3-4CF8-A2E3-50B24E73CA61Q28596148-A6F113F1-B151-422C-B253-8CA8019E0D4AQ28597362-045730A3-FB13-44A9-9F3C-4393131AC6E5Q28652056-D0C3AD2F-AA7A-4625-9AD1-50BF73B44B34Q28730692-70A9455F-ECAC-4DB9-AAB3-F796A9AE14BBQ29416989-F5B02122-12CD-4CB9-8401-0CB0A49EE8DBQ29614552-D4C06CCC-9418-4397-B84F-9A35939008BEQ29619206-0770B2B1-7779-4ECE-A624-1C2DC952CE3DQ30000080-F0013F87-107E-4727-8335-A6B9DD912AEAQ30374367-8255DFFC-FE10-4402-9C4C-C8B390400D37Q30458477-EC441F85-87AB-4B07-B4A7-01A8ECF66C2EQ30484637-20E26991-9F41-4EFF-8E78-8651F76A647FQ30660858-AFAA1F92-327C-43F1-A928-9E48BBDDEA6AQ33179111-BA428837-2CE7-445C-9F59-3E24E757E428Q33182519-D378DE4E-2A69-4E60-B65F-209D36EB05FFQ33200761-0BF53BFC-E48A-4FCD-8B6B-F80F91259369Q33269177-F783A477-0D60-4294-89B7-11B760BAE7DCQ33296082-ADEBCBDB-D83F-4028-9982-F0774BECCC78Q33330850-63634419-A1B2-46B4-BF59-E239209FA8E2Q33354606-BDC742F4-C1D2-4066-98B4-18D9946CBA48Q33430491-6AE038B6-5A75-4991-A361-0BE928EB9FC3
P50
description
academisch docent
@nl
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Peter Devilee
@ast
Peter Devilee
@en
Peter Devilee
@es
Peter Devilee
@nl
Peter Devilee
@sl
type
label
Peter Devilee
@ast
Peter Devilee
@en
Peter Devilee
@es
Peter Devilee
@nl
Peter Devilee
@sl
altLabel
Devilee P
@en
P. Devilee
@nl
prefLabel
Peter Devilee
@ast
Peter Devilee
@en
Peter Devilee
@es
Peter Devilee
@nl
Peter Devilee
@sl
P1006
P214
P1006
P21
P214
P31
P496
0000-0002-8023-2009
P735
P7449
PRS1252308
P7859
viaf-5222818